×
For best experience we recommend to activate Javascript in your browser.
Recombinant LAG3 (Fianlimab Biosimilar) antibody
The Human Monoclonal anti-LAG3 (Fianlimab Biosimilar) antibody is suitable to detect LAG3 (Fianlimab Biosimilar) in samples from Human.
Catalog No. ABIN7597690
$401.14
Plus shipping costs $50.00, if applicable $20.00 dry ice
1 mg ABIN7598295
100 μg ABIN7597690
1 mg ABIN7598295
100 μg ABIN7597690
Delivery in 12 to 15 Business Days
Quick Overview for Recombinant LAG3 (Fianlimab Biosimilar) antibody (ABIN7597690)
Target
LAG3 (Fianlimab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for LAG3 (Fianlimab Biosimilar) antibodies
Human
Clonality
All clonalities for LAG3 (Fianlimab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for LAG3 (Fianlimab Biosimilar) antibodies
This LAG3 (Fianlimab Biosimilar) antibody is un-conjugated
Application
Please inquire
Grade
Research Grade
Product Details anti-LAG3 (Fianlimab Biosimilar) Antibody
(hide)
Expression System
Mammalian cells
Purpose
Research Grade Fianlimab Biosimilar Antibody
Specificity
FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3
Purification
Protein A or G purified from cell culture supernatant.
Purity
>95 % by SDS-PAGE.
Isotype
IgG4 kappa
Alternatives
(show)
Application Details
(hide)
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
1 mg/mL
Buffer
0.01M PBS, pH 7.4.
Storage
4 °C,-20 °C,-80 °C
Storage Comment
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.Store at +4°C short term (1-2 weeks).Store at -20 °C 12 months. Store at -80°C long term.
Expiry Date
12 months
Target Details for LAG3 (Fianlimab Biosimilar)
(hide)
Target
LAG3 (Fianlimab Biosimilar)
Alternative Name
Fianlimab Biosimilar
Target Type
Biosimilar
Background
FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3
UniProt
P18627
CAS-No
2126132-98-5
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-LAG3 (Fianlimab Biosimilar) antibody (ABIN7597690)
Chat with us , powered by LiveChat